Editorial Comment on: Low-Activity V89L Variant in SRD5A2 Is Associated with Aggressive Prostate Cancer Risk: An Explanation for the Adverse Effects Observed in Chemoprevention Trials Using 5-Alpha-Reductase Inhibitors

✍ Scribed by Tommaso Prayer-Galetti

• Book ID: 113610035
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 107 KB
• Volume: 52
• Category: Article
• ISSN: 0302-2838
• DOI: 10.1016/j.eururo.2007.04.009